Navigation Links
FASgen Announces a New Discovery in Obesity Research
Date:12/21/2007

BALTIMORE, Dec. 21 /PRNewswire/ -- FASgen is pleased to report the publication of important new research results in the obesity field using FAS89B, one of the Company's proprietary compounds. FASgen is a leader in the field of research into selective inhibition of fatty acid synthase (FASi), and has conducted extensive research in the area of metabolic disease disorders, specifically for the treatment of obesity and fatty liver disease. The Company has a long-standing cooperation with The Johns Hopkins University, and that joint research has produced the new discoveries in the regulation of weight loss by the stimulation of carnitinepalmitoyl-transferase-1 (CPT-1). FAS89B was characterized in vitro as a selective inhibitor of brain CPT-1 and produced in vivo results in mice of decreased feeding for three days and persistent weight loss of six days, with no evidence of conditioned taste aversion. See, "Pharmacological Stimulation of Brain Carnitine-Transerase-1 Decreases Food Intake and Body Weight," Ronnett, et al, Am J Physiol Regul Integr Physiol (December 8, 2007). This new discovery adds another tool for FASgen to use, in addition to FASi and GPATi compounds already in research, in its ongoing program of research into the field of treatment for obesity and fatty liver disease.

About FASgen, Inc.: FASgen, Inc. is a drug development company founded in 2000 by four distinguished Johns Hopkins researchers to create new therapeutic products based on the selective inhibition of fatty acid biosynthesis. The Company has the exclusive license from Johns Hopkins to more than 15 years of research in the field, which research continues under a sponsored research agreement with the University.

The Company has designed and synthesized many compounds that selectively inhibit fatty acid biosynthesis. One group of these compounds holds great promise for new highly specific therapeutics for cancer; additional compounds have the potential of specific therapeutics for obesity and related metabolic disorders; and, an additional group of compounds have the potential of specific therapeutics for TB, including multiple drug resistant TB (MDR-TB) and latent TB infections that affect one third of the world's population. For more information, visit FASgen's website at http://www.fasgen.com.


'/>"/>
SOURCE FASgen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. FASgen Announces Significant Milestone in Its Cancer Drug Development Program
2. FASgen Announces New Discovery for Treatment of Stroke
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2018)... ... August 03, 2018 , ... LifeWIRE’s innovative patents in healthcare ... the 5,000-strong association of app companies and information technology firms across the mobile ... Method System and Computer Program Product” and subsequent patents are among those recognized ...
(Date:8/2/2018)... Texas (PRWEB) , ... August 02, 2018 , ... ... Joseph Health Regional Hospital (SJHRH) with four awards on Wednesday, July 11, 2018, ... life-saving medications and treatments to their patients. , , ...
(Date:8/2/2018)... ... 02, 2018 , ... UMD Professor Utpal Pal leads a team of investigators ... the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes ... of ticks that contribute to the spread of major diseases like Lyme disease. Pal ...
Breaking Medicine Technology:
(Date:8/17/2018)... ... ... Charles E. Crutchfield III, MD, and Crutchfield Dermatology (Eagan, Minnesota) recently assisted ... with his scoliosis (abnormal curvature of the spine) at the Minnesota Zoo (Apple Valley, ... Some types of scoliosis are caused by an abnormal and persistent contraction of muscles ...
(Date:8/15/2018)... ... August 15, 2018 , ... Nowadays, it’s fairly common knowledge that ... moisturizers and serums are known to seep into your bloodstream and accumulate in your ... become more and more informed about the quality of our skincare products, more of ...
(Date:8/14/2018)... , ... August 14, 2018 , ... ... be the keynote speaker at ChiroTouch Connect User Conference. The ChiroTouch Conference is ... Chiropractic Association (FCA). , ChiroTouch is ecstatic to have Kathy Mills Chang ...
(Date:8/14/2018)... (PRWEB) , ... August 14, 2018 , ... ... dental support organizations (DSO) with nearly 400 affiliated offices across 16 states, is ... in San Diego, California. , Smile Brands will provide full-service administrative support ...
(Date:8/11/2018)... ... , ... Dr. Siavash Eftekhari, Oral and Maxillofacial Surgeon at Monarch Dental® ... trip to deliver dental care in impoverished communities. Along with a team of fellow ... time to help deliver care to over 550 individuals in need. , This outreach ...
Breaking Medicine News(10 mins):